Lonza Group AG | 328.30 |
Date/Time | 06/28 / 17:20 |
Chg. / Chg.(%) | - / |
Bid | 312.80 / 169 |
Ask | 332.90 / 1000 |
Open | 323.80 |
Previous Close | 324.30 |
High | 328.50 |
Low | 322.50 |
Volume [CHF] | 15,621,186.95 |
Volume [Units] | 47,868 |
Price fixings | 1873 |
ISIN | CH0013841017 |
Security | LONN/Z |
Exchange | Cboe Europe CXE |
Type | Stock |
Other Exchanges
Exchange | Last | Volume | |
---|---|---|---|
Lang & Schwa.. | 541.600 | ![]() |
|
SIX Swiss Ex.. | 587.40 | ![]() |
279,020 |
London Inter.. | 587.40 | ![]() |
33,699 |
Nasdaq Other.. | 663.0400 | ![]() |
103 |
Mexico | 13,159.94 | ![]() |
270 |
Cboe Europe .. | 328.30 | 47,868 | |
Turquoise | 328.30 | ![]() |
18,782 |
Cboe Europe .. | 328.00 | 12,923 | |
TradeGate | 294.000 | 298 | |
Frankfurt | 293.9000 | 63 | |
Düsseldorf | 291.20 | 0 | |
München | 291.30 | 0 | |
Berlin | 296.90 | 0 | |
Hamburg | 291.30 | 0 | |
gettex | 296.100 | ||
Singapore | 79.97 | 500 | |
EUREX | Options |
News
- Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications
01/12/2021 / 15:05 - GlobeNewswire - Achilles Therapeutics Appoints Arjan Roozen as VP, Site Head and General Manager
01/08/2021 / 13:00 - GlobeNewswire - Arbor Biotechnologies and Lonza Enter into Gene Editing Technology Licensing Deal
12/23/2020 / 14:00 - GlobeNewswire - Altimmune Adds Lonza as a Manufacturing Partner for Supply of AdCOVID™ its Single-Dose Intranasal Vaccine Candidate for COVID-19
11/10/2020 / 07:00 - GlobeNewswire - Institutional Investor Research Publishes 2020 Europe Executive Team Rankings
09/04/2020 / 07:00 - GlobeNewswire